Search In this Thesis
   Search In this Thesis  
العنوان
Pentraxin-3 Levels in Β-thalassemia Patients /
المؤلف
El Ashmawy, Ramy Ashmawy Ahmed.
هيئة الاعداد
باحث / رامى عشماوى أحمد العشماوى
مشرف / أ.د/ فريدة حسين الرشيدي
مشرف / أ.د/ سهام محمد رجب
مشرف / أ.د/ أشرف عبد الفتاح داوود
الموضوع
Pediatrics. Thalassemia.
تاريخ النشر
2023.
عدد الصفحات
120 p. :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
طب الأطفال ، الفترة المحيطة بالولادة وصحة الطفل
تاريخ الإجازة
22/2/2023
مكان الإجازة
جامعة المنوفية - كلية الطب - طب الأطفال
الفهرس
Only 14 pages are availabe for public view

from 133

from 133

Abstract

Thalassemia is one of the most common inherited hemoglobinopathies in the world. Thalassemia’s are a heterogeneous set of disorders of genes resultant from faults in genes production α or β-globin chains. β-thalassemia comes from a fault in β-globulin chain making that gives various results varying from severe anemia to clinically asymptomatic persons. The worldwide incidence rate is valued at one per 100,000.
The disorder influences all genders but have a higher prevalence in certain ethnicities and age levels. The β- form of thalassemia is particularly prevalent among the Mediterranean peoples, and this geographical association is responsible for its naming. In Egypt, β-thalassemia is the commonest form of chronic hemolytic anemia.
Pentraxins (PTX-3) is abundantly produced by vascular endothelial cells and smooth muscle cells in response to the inflammation and oxidized low-density lipoprotein (LDL). These findings form the basis for the start of tests to understand whether or not PTX-3 can serve as a marker for the early diagnosis of vascular diseases.
It is suggested that PTX-3 increases with oxidant stress and can be used as an early diagnostic marker for inflammation. Vascular endothelial function impairment study is limited in thalassemia patients. It is predicted that PTX-3 can be an indicator of vascular endothelial damage occurring with oxidative stress, and the evaluation of endothelial function can serve as a prognostic factor for cardiovascular diseases.
So, this study aimed to evaluate Pentraxin-3 (PTX-3) in β-thalassemia major, intermediate and minor Patients and its relationship with antioxidant capacity and total oxidant stress.
To elucidate our results, this was a cross section case control study was conducted on 60 patients with Β-thalassemia (major, intermedia and minor) diagnosed by both clinical and laboratory criteria. They were enrolled from the Hematology and Oncology Unit, Pediatric Department, Menoufia University. Thirty age and sex matched healthy volunteers’ children were also included as a control group during the period from January2020 to January2022.